美国食品药品监督管理局（FDA）官员Makary近日发表声明，对Hims & Hers Health Inc.决定停止推广未经批准的复方药物表示赞赏。该公司将转向通过与新合作伙伴诺和诺德（Novo）建立的合作关系，专门销售获得FDA正式批准的医药产品。
这一战略调整标志着Hims在合规经营和产品质量管控方面迈出重要一步。通过采用经FDA严格审批的标准化药物，既能保障患者用药安全，又有助于提升企业品牌信誉。与诺和诺德的合作预计将拓宽其合规产品的市场覆盖范围。
行业观察人士指出，此举可能对在线医疗平台的产品监管合规性产生示范效应。随着监管环境日趋严格，更多企业或将重新评估其复方药物的营销策略。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.